1. Executive Summary (Confidence: High)

Neurosoft Bioelectronics is addressing one of the most critical bottlenecks in the field of neural engineering: the mechanical mismatch between rigid electronics and the soft, moving tissue of the human brain. Spun out of EPFL and based at Campus Biotech in Geneva, the organization produces interfaces that are 100,000 times softer and 5 times thinner than traditional neural probes. This innovation allows for minimally invasive implantation, significantly reduced scarring, and access to deep cortical areas such as the brain sulci.

In February 2026, the company entered a major multiyear partnership with Science Corporation, granting it access to a world-class clinical-grade BCI technology stack. This partnership accelerates the company’s ability to scale its proprietary "NeuroAI" and foundational brain models. With lead programs in epilepsy mapping and the first BCI-based treatment for severe tinnitus (SOFT TINNIT), Neurosoft is positioned to redefine the treatment of chronic neurological injury.